Page 257 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 257
P0789 EFFECTIVENESS, SAFETY AND COST PER SVR IN GT4 ePOSTERS
P0790 HEPATITIS C PATIENTS TREATED WITH SOFOSBUVIR-
P0791 BASED THERAPIES IN REAL CLINICAL PRACTICE: A
FRANCO-GERMAN EXPERIENCE (SOFEX-4)
P0792 Raluca Pais*, Peter Buggisch, Joseph Moussalli,Yves Benhamou,
Heiner Wedemeyer, Tarik Asselah, Melina Bec, Jeremie Schwarzbard,
Vlad Ratziu, Jörg Petersen, France
THE EFFECT OF RENAL IMPAIRMENT ON MULTIPLE-
DOSE PHARMACOKINETICS OF THE FIXED-DOSE
COMBINATION OF DACLATASVIR/ASUNAPREVIR/
BECLABUVIR
Robert Adamczyk*, Karen Sims, Michael Hesney,
Megan Wind-Rotolo, Michele Stonier, Ruth Penn, Laurie Reynolds,
Frank LaCreta, Malaz AbuTarif, The United States
DACLATASVIR (DCV) COMBINED WITH SOFOSBUVIR
(SOF) OR SIMEPREVIR (SMV) IN LIVER TRANSPLANT (LT)
RECIPIENTS WITH SEVERE RECURRENT HCV GENOTYPE 1
INFECTION
Robert J. Fontana*, Robert Brown, Jr.Kerstin Herzer, Rudolf E. Stauber,
Ana Moreno-Zamora, Maria-Carloto Londono, Martin Prieto,
Lluis Castells, Kristina Chacko, Peter Ferenci, Syed-Mohammed Jafri,
Viola Knop, Ranjeeta Bahirwani, Christine Durand, Raffaella Lionetti,
Laura Loiacono, Christoph Berg, Shobha Joshi, Marzia Montalbano,
Abdullah Mubarak, Adriano Pellicelli, Ahmed Elsharkawy,
Stephen Stenmark, Carlo Torti, Francis Vekeman, Raluca Ionescu-Ittu,
Bruno Edmond, Rajender Reddy, The United States
BASELINE FACTORS ASSOCIATED WITH INCREASED
SVR RATES IN 123 TREATMENT-NAÏVE CHRONIC HCV
GENOTYPE 1 PATIENTS TREATED WITH A SHORTENED 12-
WEEK SIMEPREVIR PLUS PEGYLATED INTERFERON AND
RIBAVIRIN REGIMEN: A MULTIVARIATE ANALYSIS
Tarik Asselah*, Christophe Moreno, Christoph Sarrazin,
Michael Gschwantler, Graham R. Foster, Antonio Craxi, Peter Buggisch,
Robert Ryan, Oliver Lenz, Gino Van Dooren, Isabelle Lonjon-Domanec,
Michael Schlag, Maria Buti, France
Vienna, Austria • April 22–26, 2015 257
P0790 HEPATITIS C PATIENTS TREATED WITH SOFOSBUVIR-
P0791 BASED THERAPIES IN REAL CLINICAL PRACTICE: A
FRANCO-GERMAN EXPERIENCE (SOFEX-4)
P0792 Raluca Pais*, Peter Buggisch, Joseph Moussalli,Yves Benhamou,
Heiner Wedemeyer, Tarik Asselah, Melina Bec, Jeremie Schwarzbard,
Vlad Ratziu, Jörg Petersen, France
THE EFFECT OF RENAL IMPAIRMENT ON MULTIPLE-
DOSE PHARMACOKINETICS OF THE FIXED-DOSE
COMBINATION OF DACLATASVIR/ASUNAPREVIR/
BECLABUVIR
Robert Adamczyk*, Karen Sims, Michael Hesney,
Megan Wind-Rotolo, Michele Stonier, Ruth Penn, Laurie Reynolds,
Frank LaCreta, Malaz AbuTarif, The United States
DACLATASVIR (DCV) COMBINED WITH SOFOSBUVIR
(SOF) OR SIMEPREVIR (SMV) IN LIVER TRANSPLANT (LT)
RECIPIENTS WITH SEVERE RECURRENT HCV GENOTYPE 1
INFECTION
Robert J. Fontana*, Robert Brown, Jr.Kerstin Herzer, Rudolf E. Stauber,
Ana Moreno-Zamora, Maria-Carloto Londono, Martin Prieto,
Lluis Castells, Kristina Chacko, Peter Ferenci, Syed-Mohammed Jafri,
Viola Knop, Ranjeeta Bahirwani, Christine Durand, Raffaella Lionetti,
Laura Loiacono, Christoph Berg, Shobha Joshi, Marzia Montalbano,
Abdullah Mubarak, Adriano Pellicelli, Ahmed Elsharkawy,
Stephen Stenmark, Carlo Torti, Francis Vekeman, Raluca Ionescu-Ittu,
Bruno Edmond, Rajender Reddy, The United States
BASELINE FACTORS ASSOCIATED WITH INCREASED
SVR RATES IN 123 TREATMENT-NAÏVE CHRONIC HCV
GENOTYPE 1 PATIENTS TREATED WITH A SHORTENED 12-
WEEK SIMEPREVIR PLUS PEGYLATED INTERFERON AND
RIBAVIRIN REGIMEN: A MULTIVARIATE ANALYSIS
Tarik Asselah*, Christophe Moreno, Christoph Sarrazin,
Michael Gschwantler, Graham R. Foster, Antonio Craxi, Peter Buggisch,
Robert Ryan, Oliver Lenz, Gino Van Dooren, Isabelle Lonjon-Domanec,
Michael Schlag, Maria Buti, France
Vienna, Austria • April 22–26, 2015 257
